调查行为风险因素监测系统中电子烟吸烟者的前列腺特异性抗原筛查模式。

IF 2.4 3区 医学 Q3 ONCOLOGY
Filippo Dagnino, Zhiyu Qian, Muhieddine Labban, Daniel Stelzl, Hanna Zurl, Stephan Korn, Edoardo Beatrici, Giovanni Lughezzani, Nicolò M Buffi, Stuart R Lipsitz, Adam S Kibel, Nora Osman, Quoc-Dien Trinh, Alexander P Cole
{"title":"调查行为风险因素监测系统中电子烟吸烟者的前列腺特异性抗原筛查模式。","authors":"Filippo Dagnino, Zhiyu Qian, Muhieddine Labban, Daniel Stelzl, Hanna Zurl, Stephan Korn, Edoardo Beatrici, Giovanni Lughezzani, Nicolò M Buffi, Stuart R Lipsitz, Adam S Kibel, Nora Osman, Quoc-Dien Trinh, Alexander P Cole","doi":"10.1016/j.urolonc.2024.09.036","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and objectives: </strong>E-cigarettes use has recently increased, even among older individuals quitting smoking. Though past studies suggest tobacco smokers may avoid cancer screening, the relationship between e-cigarette uses and preventive health behaviors like prostate specific antigen screening is uncertain. We assessed the relationship between self-reported e-cigarette smoking and prostate specific antigen screening utilization among US adults with a history of e-cigarette use.</p><p><strong>Materials and methods: </strong>We included men aged 50-69 years, who provided responses regarding PSA screening receipt and smoking status, from Behavioral Risk Factor Surveillance System 2020 and 2022 surveys. Primary outcome was PSA screening receipt. Multivariable regression model was performed to investigate the association between smoking status (never-smokers, current or former e-cigarette smokers, current or former tobacco smokers) and PSA screening.</p><p><strong>Results: </strong>We included a weighted population of 8.1 million men aged 50-69. 2.3 million (28.3%) received PSA screening. 3.9 million (48.2%) were never-smokers. 1.3 million (16.6%) were from e-cigarettes smokers group, and 2.9 million (35.2%) were from tobacco smokers group. E-cigarettes smokers were less likely to receive PSA screening within last 2 years (0.76 [0.66-0.88]) than never-smokers. No significant difference in PSA screening was detected between never-smokers and tobacco smokers (0.91 [0.82-1.02]). E-cigarette smokers were less likely to receive PSA screening within the selected time frame (0.84 [0.72-0.97]) than tobacco smokers. When examining potential mediation by primary care visits, e-cigarette smokers were less likely to have had a check-up visit in past 2 years than tobacco smokers (0.77 [0.65-0.92]).</p><p><strong>Conclusions: </strong>E-cigarette smokers were less likely to undergo PSA screening than never-smokers and tobacco smokers, possibly due to reduced use of primary care services.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Investigating the pattern of prostate specific antigen screening among E-cigarette smokers within the behavioral risk factor surveillance system.\",\"authors\":\"Filippo Dagnino, Zhiyu Qian, Muhieddine Labban, Daniel Stelzl, Hanna Zurl, Stephan Korn, Edoardo Beatrici, Giovanni Lughezzani, Nicolò M Buffi, Stuart R Lipsitz, Adam S Kibel, Nora Osman, Quoc-Dien Trinh, Alexander P Cole\",\"doi\":\"10.1016/j.urolonc.2024.09.036\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction and objectives: </strong>E-cigarettes use has recently increased, even among older individuals quitting smoking. Though past studies suggest tobacco smokers may avoid cancer screening, the relationship between e-cigarette uses and preventive health behaviors like prostate specific antigen screening is uncertain. We assessed the relationship between self-reported e-cigarette smoking and prostate specific antigen screening utilization among US adults with a history of e-cigarette use.</p><p><strong>Materials and methods: </strong>We included men aged 50-69 years, who provided responses regarding PSA screening receipt and smoking status, from Behavioral Risk Factor Surveillance System 2020 and 2022 surveys. Primary outcome was PSA screening receipt. Multivariable regression model was performed to investigate the association between smoking status (never-smokers, current or former e-cigarette smokers, current or former tobacco smokers) and PSA screening.</p><p><strong>Results: </strong>We included a weighted population of 8.1 million men aged 50-69. 2.3 million (28.3%) received PSA screening. 3.9 million (48.2%) were never-smokers. 1.3 million (16.6%) were from e-cigarettes smokers group, and 2.9 million (35.2%) were from tobacco smokers group. E-cigarettes smokers were less likely to receive PSA screening within last 2 years (0.76 [0.66-0.88]) than never-smokers. No significant difference in PSA screening was detected between never-smokers and tobacco smokers (0.91 [0.82-1.02]). E-cigarette smokers were less likely to receive PSA screening within the selected time frame (0.84 [0.72-0.97]) than tobacco smokers. When examining potential mediation by primary care visits, e-cigarette smokers were less likely to have had a check-up visit in past 2 years than tobacco smokers (0.77 [0.65-0.92]).</p><p><strong>Conclusions: </strong>E-cigarette smokers were less likely to undergo PSA screening than never-smokers and tobacco smokers, possibly due to reduced use of primary care services.</p>\",\"PeriodicalId\":23408,\"journal\":{\"name\":\"Urologic Oncology-seminars and Original Investigations\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-10-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urologic Oncology-seminars and Original Investigations\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.urolonc.2024.09.036\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologic Oncology-seminars and Original Investigations","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.urolonc.2024.09.036","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言和目标:电子烟的使用最近有所增加,甚至在戒烟的老年人中也是如此。尽管过去的研究表明吸烟者可能会避免癌症筛查,但电子烟的使用与前列腺特异性抗原筛查等预防性健康行为之间的关系尚不确定。我们评估了有电子烟使用史的美国成年人自我报告的电子烟吸烟与前列腺特异性抗原筛查利用率之间的关系:我们纳入了 2020 年和 2022 年行为风险因素监测系统调查中提供有关接受前列腺特异性抗原筛查和吸烟状况答复的 50-69 岁男性。主要结果是接受过 PSA 筛查。采用多变量回归模型研究吸烟状态(从不吸烟者、目前或曾经吸电子烟者、目前或曾经吸烟者)与 PSA 筛查之间的关系:我们纳入了 810 万 50-69 岁男性的加权人口。230万人(28.3%)接受了PSA筛查。390万人(48.2%)从未吸烟。130万人(16.6%)为电子烟烟民,290万人(35.2%)为烟草烟民。与从不吸烟者相比,吸电子烟者在过去两年内接受 PSA 筛查的可能性较低(0.76 [0.66-0.88])。从未吸烟者和吸烟者在 PSA 筛查方面没有发现明显差异(0.91 [0.82-1.02])。与吸烟者相比,吸电子烟者在选定时间内接受 PSA 筛查的可能性较低(0.84 [0.72-0.97])。在研究初级保健就诊的潜在中介作用时,电子烟烟民在过去两年中进行体检的可能性低于烟草烟民(0.77 [0.65-0.92]):结论:与从不吸烟者和吸烟者相比,电子烟烟民接受 PSA 筛查的可能性较低,这可能是由于减少了对初级保健服务的使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Investigating the pattern of prostate specific antigen screening among E-cigarette smokers within the behavioral risk factor surveillance system.

Introduction and objectives: E-cigarettes use has recently increased, even among older individuals quitting smoking. Though past studies suggest tobacco smokers may avoid cancer screening, the relationship between e-cigarette uses and preventive health behaviors like prostate specific antigen screening is uncertain. We assessed the relationship between self-reported e-cigarette smoking and prostate specific antigen screening utilization among US adults with a history of e-cigarette use.

Materials and methods: We included men aged 50-69 years, who provided responses regarding PSA screening receipt and smoking status, from Behavioral Risk Factor Surveillance System 2020 and 2022 surveys. Primary outcome was PSA screening receipt. Multivariable regression model was performed to investigate the association between smoking status (never-smokers, current or former e-cigarette smokers, current or former tobacco smokers) and PSA screening.

Results: We included a weighted population of 8.1 million men aged 50-69. 2.3 million (28.3%) received PSA screening. 3.9 million (48.2%) were never-smokers. 1.3 million (16.6%) were from e-cigarettes smokers group, and 2.9 million (35.2%) were from tobacco smokers group. E-cigarettes smokers were less likely to receive PSA screening within last 2 years (0.76 [0.66-0.88]) than never-smokers. No significant difference in PSA screening was detected between never-smokers and tobacco smokers (0.91 [0.82-1.02]). E-cigarette smokers were less likely to receive PSA screening within the selected time frame (0.84 [0.72-0.97]) than tobacco smokers. When examining potential mediation by primary care visits, e-cigarette smokers were less likely to have had a check-up visit in past 2 years than tobacco smokers (0.77 [0.65-0.92]).

Conclusions: E-cigarette smokers were less likely to undergo PSA screening than never-smokers and tobacco smokers, possibly due to reduced use of primary care services.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.80
自引率
3.70%
发文量
297
审稿时长
7.6 weeks
期刊介绍: Urologic Oncology: Seminars and Original Investigations is the official journal of the Society of Urologic Oncology. The journal publishes practical, timely, and relevant clinical and basic science research articles which address any aspect of urologic oncology. Each issue comprises original research, news and topics, survey articles providing short commentaries on other important articles in the urologic oncology literature, and reviews including an in-depth Seminar examining a specific clinical dilemma. The journal periodically publishes supplement issues devoted to areas of current interest to the urologic oncology community. Articles published are of interest to researchers and the clinicians involved in the practice of urologic oncology including urologists, oncologists, and radiologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信